Bristol Myers Squibb has secured global rights to a pair of anti-SARS-CoV-2 antibodies discovered by The Rockefeller University. The antibodies entered phase 1 development last month.
Lilly and Regeneron have already received emergency use authorizations for their anti-SARS-CoV-2 antibodies. Bamlanivimab, Lilly’s authorized antibody, generated sales of $871 million in the fourth quarter and is under a contract with the U.S. government that will provide further revenues. Lilly and Regeneron are set to face competition from companies such as AstraZeneca and potentially declining utility in a world of mass vaccination.